Estrogen receptor alpha (ERa) regulates transcription of specific genes and is believed to play a major role in breast tumorigenesis. We previously identified estrogen down regulated gene 1 (EDG1 (also known as HEXIM1)) using the C-terminus of ERa (E/F domain) as bait in yeast twohybrid screenings. Here we report on the role of EDG1 as a coregulator of ERa transcriptional activity. We observe an interaction between EDG1 and ERa. EDG1 inhibits the transcriptional activity of ERa and this is dependent upon the C-terminus of EDG1. The C-terminus of EDG1/ HEXIM1 was recently shown to inhibit the positive transcription elongation factor b (P-TEFb) by interacting with the cyclin T1 subunit. Here we show that ERa interacts with cyclin T1, cyclin T1 and ER co-occupancy on the promoter region of an ER target gene, and that this interaction plays an important role in ERa-induced gene expression. The interaction of ERa with cyclin T1 also allows ERa to compete with EDG1 for cyclin T1, and may release cyclin T1 from EDG1 repression. Conversely, increased EDG1 expression results in inhibition of cyclin T1 recruitment and ERa DNA binding. Our results support a novel functional interaction between ERa and cyclin T1 that is modulated by EDG1.
Introduction
We previously identified the novel inhibitor of breast cell growth, estrogen down regulated gene 1 (EDG1), using the C-terminus (E/F domain) of estrogen receptor alpha (ERa) as bait in yeast two-hybrid screenings. We also showed that EDG1 could inhibit breast cell growth and that estrogen could directly down regulate EDG1 mRNA and subsequently EDG1 protein levels (Wittmann et al., 2003) . EDG1, also known as HEXIM1, was previously shown to be upregulated in vascular smooth muscle cells by the differentiating agent hexamethylenebis-acetamide (HMBA) (Kusuhara et al., 1999) . EDG1/ HEXIM1 is also homologous to the mouse protein, cardiac lineage protein 1 (CLP-1), which has been implicated as a cell-specific transcriptional mediator of the cardiac MLC-2u promoter (Huang et al., 2002) . Another study suggested that EDG1/HEXIM1 functions as a repressor of NF-kB-mediated transcription (Ouchida et al., 2003) . For the rest of the manuscript, the term EDG1 will be used in place of EDG1/ HEXIM1, unless we are referring to work previously performed on HEXIM1.
Owing to the identification of EDG1 as an ERa interacting protein and, more importantly, colocalization of EDG1 with ERa in the nuclei of breast cells in human tissue samples, we determined if EDG1 has effects on the function of ERa. ERa, a member of the large superfamily of nuclear receptors, activates transcription from the promoters that contain estrogen receptor response elements (EREs) (Glass and Rosenfeld, 2000; Nilsson et al., 2001) . Activation of ERa by estrogens and subsequent regulation of specific genes, such as c-myc and cyclin D1, is believed to play a major role in breast tumorigenesis (Henderson et al., 1982; Flototto et al., 2001) .
Estrogen binding to the ligand-binding domain of ERa induces conformational changes in ERa and formation of ERa transcription complexes (McDonnell and Norris, 2002) . The events following the conformational changes in ERa include: ERa dimerization, binding to DNA, interaction with coactivators and other transcription factors (typically through the E/F domain of ERa), and finally transcriptional regulation of gene expression. ERa recruitment of coactivators such as p160 family members (SRC1, GRIP1, and AIB1), p300/CBP, pCAF, and mammalian Mediator complex assist in decondensing nucleosomes and in the formation of the preinitiation complex, which includes unphosphorylated RNA polymerase II (RNAP II) (Shang et al., 2000; Metivier et al., 2003) . The cyclical order of recruitment of these numerous proteins responsible for the initiation of transcription by ERa has been dissected using chromatin immunoprecipitation (ChIP) assays (Shang et al., 2000; Metivier et al., 2003) .
The formation of the preinitiation complex alone is not sufficient for production of full-length transcripts. The carboxy terminal domain (CTD) of RNAP II is composed of 52 heptapeptide repeats (consensus sequence: YSPTSPS), which must be phosphorylated for transition into productive elongation (Marshall et al., 1996; Spencer et al., 1997; Kim and Sharp, 2001) . Two specific kinases involved in the phosphorylation of CTD include cyclin-dependent kinase 7 (CDK7)/cyclin H of TFIIH and P-TEFb (Positive transcription elongation factor b) (CDK9/cyclin (T1, T2a, or T2b)), which preferentially phosphorylate Ser 5 and Ser 2 of the heptapeptide repeats, respectively (Spencer et al., 1997) . Recent studies further demonstrated that EDG1/HEXIM1 binds to cyclin T1 through its carboxy terminus and functions as an inhibitor of PTEFb activity (Michels et al., 2003; Yik et al., 2003) .
Here we report that a novel inhibitor of breast cell growth, EDG1, inhibits the transcriptional activity of ERa. The repression of ERa transcriptional activity is dependent upon the C-terminus of EDG1. Although we show that EDG1 can interact in vitro with E/F domain of ERa and can immunoprecipitate ERa from MCF7 cells, this interaction does not appear to be sufficient for repression of transcription by EDG1. Further studies suggest that the basis for this inhibitory effect may involve the repressive effects of EDG1 on cyclin T1. With increased EDG1 expression, cyclin T1 would remain inactive and perhaps is the basis for our observed inhibition of ERa DNA binding. Indeed, overexpression of cyclin T1 rescued ERa transcription from the inhibitory effect of EDG1. Moreover, ERa interacts with cyclin T1 in vitro and in vivo, and competes with EDG1 for interaction with cyclin T1. These results suggest a possible mechanism involving an interplay between negative and positive regulators of ERa transcription.
Results

EDG1 interacts with ERa and inhibits ERa transcriptional activity
We have previously observed colocalization of ERa and EDG1 in the nuclei of breast cells in human tissues samples (Wittmann et al., 2003) . Co-immunoprecipitation assays were performed to determine if endogenous EDG1 and ERa interacted in breast cell lines. EDG1 interacted with ERa from both untreated and transhydroxytamoxifen (TOT)-treated ERa-positive MCF7 breast cancer cells (Figure 1a , lanes 5 and 7). Although interaction between endogenous EDG1 and ERa was weaker from 17b-estradiol (E 2 )-treated cells (Figure 1a , lane 6), this could be attributed to decreased ERa levels following E 2 treatment (Figure 1a , input lane 2). EDG1 was also able to co-immunoprecipitate ERa from ERapositive breast cancer cell line T47D (Figure 1a , lane 11), while as expected, EDG1 was unable to coimmunoprecipitate ERa from two ERa-negative cell lines MCF10A and MDA MB-231 ( Figure 1a , lanes 10 and 13). We observed a nonspecific band (NSB) in the 10% input lane for MCF10A and MDA MB-231 cells that was not immunoprecipitated by the EDG1 antibody ( Figure 1a, lanes 8 and 12) .
We then determined if EDG1 could affect the activation by E 2 -liganded ERa of a chloramphenicol acetyltransferase (CAT) reporter plasmid containing the pS2 gene promoter downstream of two EREs. Transfection of expression vector for EDG1, pCMV5-EDG1, resulted in inhibition of the transcriptional activity of both exogenous (Figure 1b ) and endogenous ( Figure 1c ) E 2 -liganded ERa in CHO and MCF7 cells, respectively. The amount of expression vectors for ERa transfected into CHO cells represents the amount required for optimal activation of corresponding reporter activity.
The C-terminus of EDG1 is necessary for repression of ERa transcriptional activity and has intrinsic transcriptional repressive activity
To determine the region(s) of EDG1 necessary for repression of ERa activity, deletion mutants of EDG1 were constructed. CHO cells were then transfected with either pCMV-TAG2B-EDG1 or pCMV-TAG2B-EDG1 deletion mutants. These expression vectors allowed for wild-type or mutant EDG1 to be expressed as FLAG epitope-tagged proteins (FLAG-EDG1). A large difference in expression was observed between FLAG-EDG1 full-length and FLAG-EDG1 mutants 24 h following transfection ( Figure 2a and data not shown). We therefore determined the amount of each FLAG-EDG1 mutant plasmids that would allow for equivalent or higher expression of C-terminus FLAG-EDG1 mutants as compared to wild-type FLAG-EDG1 10 h following transfection (Figure 2b ). Using equivalent amounts of FLAG-EDG1 plasmid as determined in Figures 2a and b , reporter assays were performed 10 h following transfection. Repression of ERa-mediated transcription was observed with wild-type FLAG-EDG1 and the N-terminus mutants FLAG-EDG1 and FLAG-EDG1 (Figure 2c ). Only 20% repression was observed when the nuclear localization signal (NLS) was mutated as in the FLAG-EDG1 (D150-177) deletion mutant. However, the levels of repression observed with wild-type FLAG-EDG1 and FLAG-EDG1 (D150-177) deletion mutant were not statistically significantly different from each other. We did not observe repression of ERa transcriptional activity by FLAG-EDG1 C-terminus deletion mutants (FLAG-EDG1 and FLAG-EDG1 , Figure 2c ), even though they were expressed at equal or higher levels than the wild-type FLAG-EDG1 (Figure 2a and b) . It should be noted that differences in the amount of FLAG-EDG1 expression vector required for repression of ER activity in Figures 1 and 2c are perhaps due to the different expression plasmids, pCMV5-EDG1 vs Normal rabbit IgG was used as control (lane 4). In the panels, 'input' lane represents 10% of the total volume of lysate used in each reaction. The autoradiograph is representative of two separate experiments. (b) CHO cells were transfected with expression vector for ERa (5 ng) and (ERE) 2 -pS2-CAT reporter construct (2 mg). The cells were cotransfected with pCMV5 control expression vector or increasing concentration of an expression vector for EDG1 (pCMV5-EDG1) as indicated. (c) MCF7 cells, which express high endogenous ERa, were transfected with (ERE) 2 -pS2-CAT reporter vector. All cells were also transfected with a b-galactosidase internal control reporter to correct for transfection efficiency. Cells were then treated for 24 h with 10 À8 M 17b-estradiol (E 2 ). Values are the means7s.e. from three separate experiments. In the lower panels of (b) and (c), WCE from transfected cells were subjected to Western analyses with anti-ERa and anti-EDG1. Blots were also probed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control EDG1 repression of estrogen receptor alpha activity BM Wittmann et al pCMV-TAG2B-EDG1, respectively, used in the two sets of experiments. To determine if EDG1 has intrinsic repressor activity, we fused EDG1 N-and C-terminus to the DNA-binding domain of GAL4 and examined their ability to repress the transcriptional expression of a CAT reporter gene localized downstream of GAL4-binding sites and a constitutively active TK promoter (5X(GAL4UAS)-TK-CAT). Intrinsic repressor activity can be attributed to the C-terminus, as we observe 73% repression of 5X(GAL4UAS)-TK-CAT activity by GAL4DBD-EDG1 . GAL4DBD-EDG1 (1-280) was unable to -359) ) or FLAG-EDG1 (D150-177) NLS deletion mutant for either 10 or 24 h. Cells were harvested, lysed, and subjected to Western analyses as described in 'Materials and methods'. (b) CHO cells were transfected with expression vectors for full-length FLAG-EDG1 (FLAG-EDG1 ), N-terminus, or C-terminus deletion mutants as indicated. Cells were grown for 10 h and subjected to Western analyses as in (a). The autoradiographs are representative of two separate experiments each. (c) CHO cells were transfected with pCMV5-ERa, (ERE) 2 -TATA-CAT reporter gene, and with the same relative amount of expression vectors for FLAG-EDG1 (full-length, FLAG-EDG1 , or deletion mutants) expression vector used in (b) and treated for 10 h with 10 À8 M 17b-estradiol (E 2 ). Control cells were transfected with pCMV-TAG2B control vector. a: significantly different compared to pCMV-TAG2B control vector, P-value o0.05; b: not significantly different compared to pCMV-TAG2B control vector, P-value >0.05. (d) CHO cells were transfected with 5X(GAL4UAS)-TK-CAT and GAL4DBD-EDG1 (1 mg) or GAL4DBD-EDG1 (1 mg). Values are the means7s.e. from at least three separate experiments repress the activity of 5X(GAL4UAS)-TK-CAT (Figure 2d ). Consistent with these observations, sequence analysis indicates that the C-terminus is 96% conserved between human and the mouse homologue, CLP-1, as compared to only 65% homology in the N-terminus.
The inability of the EDG1 C-terminus deletion mutants to repress ERa-dependent transcription is not due to cellular localization or decreased interaction with ERa Next, we tested whether the inability of EDG1 Cterminus deletion mutants to repress ERa-dependent transcription was due to changes in cellular localization. CHO cells were transfected with expression vectors for FLAG-EDG1 or FLAG-EDG1 deletion mutants. The cells were then subjected to immunostaining using the anti-FLAG antibody. We observed nuclear localization of FLAG-EDG1 full-length (as previously reported in Ouchida et al., 2003) and the C-terminus FLAG-EDG1 (1-280) deletion mutant ( Figure 3a) . The other C-terminus FLAG-EDG1 (1-310) deletion mutant and the two N-terminus deletion mutants also showed nuclear localization (data not shown). Therefore, the inability of the C-terminus deletion FLAG-EDG1 mutants to repress transcription cannot be attributed to nonnuclear localization. Although the majority of the cells expressing the FLAG-EDG1 (D150-177) NLS deletion mutant showed non-nuclear localization as expected (Figure 3a) , some of the cells showed nuclear localization of the FLAG-EDG1 (D150-177) NLS deletion mutant (data not shown and as reported in Ouchida et al., 2003) . This may explain why minor repression by the FLAG-EDG1 (D150-177) NLS deletion mutant was observed in reporter assays (Figure 2c ). Although previous studies have strongly implicated the EDG1 NLS region in nuclear localization (Michels et al., 2003; Ouchida et al., 2003) , our data suggest that unknown factors, in To determine if there is a correlation with ability to bind to ERa and ability to inhibit ERa transcriptional activity, we examined the interaction of EDG1 deletion mutants with ERa using glutathione-S-transferase (GST)-pull down assays. While EDG1 full-length (FL) was identified through its interaction with the E/F domain (C-terminus) of ERa and EDG1 full-length was shown to interact with full-length ERa, we also determined if EDG1 could interact with the A/B domain (N-terminus) of ERa as well. In vitro protein-protein interaction assays showed that GST-EDG1 full-length and GST-EDG1 interacted with both in vitro translated ERa full-length and the E/F domain of ERa ( Figure 3b , lanes 4, 6, 7, and 9). GST-EDG1 full-length and GST-EDG1 (1-280) pulled down 3 and 5%, respectively, of total full-length ERa added to each reaction. Neither ERa full-length nor its E/F domain interacted with GST-control ( Figure 3b , lanes 13 and 15). In addition, GST-EDG1 , -EDG1 , -EDG1 all interacted with ERa full-length or the E/F domain of ERa (data not shown). Since EDG1 (1-310) was not able to inhibit ERa transcriptional activity, our data suggest that the interaction between ERa and EDG1 alone is not sufficient for the repression of ERa-dependent transcription. Neither GST-EDG1 full-length nor any of the GST-EDG1 mutants interacted with in vitro translated ERa A/B domain ( Figure 3b , lanes 5, 8, 11, and data not shown).
The GST-EDG1 (D150-177) NLS deletion mutant showed little to no interaction with ERa when compared with GST-EDG1 full-length ( Figure 3b , lanes 4 and 6 compared with 10 and 12). Similarly, it was previously shown that EDG1 (D150-177) NLS deletion mutant did not interact with NF-kB (Ouchida et al., 2003) . Since the EDG1 (D150-177) NLS mutant still showed slight inhibition of ERa transcription, it is unlikely that NF-kB is involved in the inhibitory effect of EDG1.
Physical and functional interaction between ERa and cyclin T1
Recent studies indicated that the C-terminus of EDG1/ HEXIM1 interacts with the N-terminus of cyclin T1, a subunit of P-TEFb. Therefore, we tested a possible interaction between ERa and cyclin T1. Our studies show that both overexpressed and endogenous ERa interacted with cyclin T1 in vivo (Figures 4a, lanes 2 and 8, lanes 12 and 15). The interaction between ERa and cyclin T1 was confirmed in in vitro GST-pull down assay using GST-ERa full-length (FL) and in vitro translated cyclin T1 full-length. This interaction appeared to be strengthened in the presence of E 2 (Figure 4b, compare lanes 3 and 4) . We then identified the regions in ERa and cyclin T1 necessary for this interaction using GST-ERa full-length, GST-ERa E/F, or GST-ERa A/B and in vitro translated cyclin T1 full-length or its truncation mutants. While C-terminus deletion mutants of cyclin T1, cyclin T1 (1-281) and T1 , bind to either GST-ERa full-length or GSTERa E/F, a much weaker interaction was observed with the cyclin T1 (232-611) mutant (Figure 4c ). GST-ERa E/F pulled down 9 and 2% of total cyclin T1 and T1 input, respectively. Interactions observed with GST-ERa A/B were not stronger than the interactions observed with GST-control (Figure 4c , compare lane 6, 9, and 12 with lanes 17-19). These observations indicate that ERa interacts with the Nterminus of cyclin T1 through its E/F domain. The functional relevance of this interaction is supported by the decrease in E 2 -induced cyclin D1 expression upon downregulation of cyclin T1 expression using cyclin T1 siRNA (Figure 4d ).
Physical and functional competition between EDG1 and ERa for cyclin T1
We then determined if ERa and EDG1 compete for interaction with cyclin T1. GST-pull down assays using 35 S-cyclin T1 and GST-EDG1 indicated that ERa and EDG1 interact with the same region (amino acids 1-227) of cyclin T1 (Figure 4c and 5a) . We then examined if incubation of in vitro translated ERa with in vitro translated cyclin T1 could inhibit the interaction of cyclin T1 with GST-EDG1 full-length (FL) bound to glutathione sepharose beads. A strong interaction was observed between GST-EDG1 full-length and either in vitro translated cyclin T1 or ERa (Figure 5b , lanes 6-10). The interaction between GST-EDG1 and cyclin T1 was reduced when ERa was incubated along with cyclin T1 (Figure 5b , compare lane 6 with lanes 11-14). GST-EDG1 pulled down 16% of total cyclin T1 input in the absence of ERa when compared to 5% in the presence of ERa.
We have shown that the NLS region of EDG1 was at least partially responsible for the interaction with ERa (Figure 3b) , and others reported that cyclin T1 interaction involved the C-terminus EDG1/HEXIM1 (Michels et al., 2003; Yik et al., 2003) . Since cyclin T1 and ERa appeared to interact with different regions of EDG1, some of the interactions observed between GST-EDG1 and cyclin T1 when ERa is present could be due to interaction of ERa with both GST-EDG1 and cyclin T1. To address this, we made use of the EDG1 NLS deletion mutant GST-EDG1 (D150-177) , whose interaction with ERa was decreased when compared with GST-EDG1 full-length (Figures 3b and 5b , (lanes 16-19 compared with 7-10)). Although the interaction between GST-EDG1 (D150-177) and cyclin T1 was comparable to that observed between GST-EDG1 full-length and cyclin T1 (Figure 5b , compare lanes 15 and 6), incubating ERa with cyclin T1 resulted in a major decrease in the ability of cyclin T1 to interact with GST-EDG1 (D150-177) . This decrease was even more significant in the presence of E 2 (Figure 5b , compare lane 15 with lanes 20-23). The competition between ERa and EDG1 for cyclin T1 was also observed in vivo using co-immunoprecipitation assays, wherein cotransfection with ERa decreased the level of interaction observed between cyclin T1 and FLAG-EDG1 (Figure 5c , compare lanes 2 and 3). GST-EDG1 (D150-177) pulled down 8% of total cyclin T1 input in the absence of ERa when compared to 2% in the presence of ERa.
We then determined if cyclin T1 interaction with ERa influences EDG1-mediated inhibition of ERa transcriptional activation using CAT reporter assays. Cotransfection of cyclin T1 expression vector into MCF7 cells enhanced ERa transcriptional activity (Figure 5d , compare lanes 2 and 4). Cotransfection with cyclin T1 mutant, which did not interact with ERa in vitro, had no effect on ERa activity (Figure 5d, lane 10) . In addition, cyclin T1 relieved EDG1 repressive effects on ERa transcriptional activity (Figure 5d , compare lanes 6 and 8). Only a slight increase in ERa basal transcriptional activity was observed in cells cotransfected with cyclin T1 (Figure 5d, compare lanes 1 and 3) . These findings support our results above indicating a competition between ERa and EDG1 for cyclin T1, and a compensatory increase in cyclin T1 favors ERa interaction to cyclin T1 and release of cyclin T1 from EDG1 repressive effects. 3 and 6-8 ). Cells were lysed and precleared with Protein A-Sepharose. Immunoprecipitations (IP) with anti-HA antibody (lanes 2 and 3), anti-ERa (lanes 7 and 8), or IgG (lanes 1 and 6) were followed by Western blotting (WB) with anti-ERa (lanes 1-3) or anti-HA (lanes 6-8). Input samples (5%) were also shown to verify the expression of HA-cyclin T1 (lanes 4, 5, 9, and 10). Endogenous ERa was immunoprecipitated from equal concentrations of WCE from MCF7 cells (lane 12), using cyclin T1 antibody, followed by Western blotting with anti-ERa. Endogenous cyclin T1 was immunoprecipitated from equal concentrations of WCE from MCF7 cells (lane 15), using ERa antibody, followed by Western blotting with anti-cyclin T1. lanes 3 and 4) . At 48 h after transfection, cells were treated for 6 h with vehicle or 10 À8 M 17b-estradiol (E 2 ) prior to harvesting. Cells were processed for Western blotting with anti-cyclin T1, anti-cyclin D1, and anti-GAPDH (for normalization). The autoradiographs are representative of 2-3 separate experiments each EDG1 and cyclin T1 are recruited to the promoter region of an ER target gene and increased EDG1 expression inhibits ERa-cyclin T1 co-occupancy in vivo
We then examined if EDG1 is recruited to chromatin, and if cyclin T1 recruitment can be correlated with EDG1 and/or ERa binding to chromatin in breast cancer cells by using ChIP assays. To complement our studies in Figure 5d , the pS2 gene promoter was selected as the ERa target gene promoter for these experiments. Moreover, serial ChIP assays were performed to verify that EDG1 or cyclin T1 are recruited simultaneously with ERa to the same promoters, as opposed to distinct subsets of promoters on different alleles or different cells.
Our results indicate binding of ERa after 45 and 90 min of E 2 treatment to the ERE-containing region of the pS2 gene promoter (Figure 6a ). We observed that EDG1 was recruited with ERa to the ERE-containing region of the pS2 gene at 90 min after E 2 treatment. Cyclin T1-ERa co-occupancy was apparent at 45 and 90 min after E 2 treatment, with more cyclin T1 binding apparent at 45 min when compared to 90 min (Figure 6a , compare lanes 3 and 4). We did not detect ERa occupancy to a region downstream of the ERE-containing region of the pS2 gene (Figure 6a, lane 1) . Since we observed competition between ERa and EDG1 for cyclin T1, we determined the effects of increased EDG1 expression on cyclin T1-ERa co-occupancy. Our results indicate that increase in EDG1 expression resulted in inhibition of ERa-cyclin T1 co-occupancy and decreased ERa binding to the ERE-containing region of the pS2 gene promoter (Figure 6b ).
Together our ChIP assay results suggest that both EDG1 and cyclin T1 are recruited to chromatin by ERa. However, with increased expression of EDG1, EDG1 is able to compete with ERa for cyclin T1 interaction and inhibit the recruitment of cyclin T1 by ERa.
Discussion
In this report we show that endogenous EDG1 and ERa can interact, and EDG1 can repress ERa transcriptional 3) and/or ERa (lanes 1 and 2). IP with anti-FLAG antibody (lanes 2 and 3) or IgG (lane 1) were followed by Western blotting (WB) with anti-cyclin T1 (lanes 1-3) . Input samples (5% of total volume of lysate used in each reaction) were also shown to verify the expression of FLAG-EDG1 (lanes 4-6) and cyclin T1 (lane 7). The autoradiographs are representative of two separate experiments each. (d) MCF7 cells, which express high endogenous ERa, were transfected with (ERE) 2 -pS2-CAT reporter vector. The cells were cotransfected with control expression vector or expression vectors for EDG1, cyclin T1, or cyclin T1 . All cells were also transfected with a b-galactosidase internal control reporter to correct for transfection efficiency. Cells were then treated for 24 h with 10 À8 M 17b-estradiol (E 2 ). Values are the means7s.e. from three separate experiments activity in breast cancer cells. This effect was dependent upon the C-terminus of EDG1. While EDG1 is recruited to chromatin via its interaction with ERa, this interaction was not sufficient for the repression of ERamediated transcription. We demonstrated that cyclin T1 plays a critical role in the interplay between ERa and EDG1. Both ERa and EDG1 bind the cyclin T1 subunit of P-TEFb and compete with each other for cyclin T1. Since EDG1 was demonstrated to be a inhibitory factor for the functions of P-TEFb (Michels et al., 2003; Yik et al., 2003) , it is likely that EDG1 inhibits ERa transcription via sequestering cyclin T1 from ERa. Our proposed model is shown in Figure 7 .
The mouse homologue, CLP-1, also shown to be predominately nuclear, can repress the promoter for the early expressed cardiac gene MLC-2u in a cell-specific manner (Huang et al., 2002) . During preparation of this manuscript, three additional manuscripts were published on the EDG1 homologue, HEXIM1 (Michels et al., 2003; Ouchida et al., 2003; Yik et al., 2003) . EDG1/HEXIM1 was shown to repress NF-kB-dependent transcription via its C-terminus and interaction with NF-kB also did not appear to be sufficient for transcriptional repression (Ouchida et al., 2003) . EDG1/ HEXIM1 was also shown to interact with 7SK snRNA and form an inactive P-TEFb complex by binding to and inhibiting the kinase activity of the CDK9 subunit of P-TEFb (Michels et al., 2003; Yik et al., 2003) . Interestingly, EDG1/HEXIM1 interaction with cyclin T1 of P-TEFb is dependent upon the C-terminus of EDG1/HEXIM1 (Michels et al., 2003) . That the regions of EDG1 necessary for its interaction with ERa are different than those responsible for interaction of EDG1 with cyclin T1 further support the interaction of EDG1 with ERa. Additionally, the region of cyclin T1 where EDG1 interacts is within the same region of cyclin T1 where the transcription factors NF-kB and c-myc interact, while RNAP II binds to a different region of cyclin T1 (Fong and Zhou, 2000; Barboric et al., 2001; Kanazawa et al., 2003; Michels et al., 2003; Yik et al., 2003) . Together these studies support our findings that EDG1 is a nuclear protein that can repress the ERa transcriptional activity by binding and inhibiting cyclin T1, a factor that appears to play an important role in ERa-induced gene expression.
Our findings suggest that ERa recruits cyclin T1 to the promoter of ERa target genes in breast cancer cells. Proteins involved in transcription, RNAP II, GRIP1, and NFkB, have been shown to interact with P-TEFb and proposed to be involved in the recruitment of P-TEFb (Fong and Zhou, 2000; Barboric et al., 2001; Kino et al., 2002) . Interestingly, the androgen receptor (another member of the nuclear hormone receptor family) has also been shown to interact with and possibly recruit P-TEFb to promoters undergoing transcription (Lee et al., 2001) . Most of the research on ERa as a regulator of transcription involves the role of ERa as an initiator of transcription and the formation of the preinitiation complex. In light of our current findings, our studies are the first to suggest an involvement of ERa in transcriptional elongation. Further studies are obviously necessary to prove this.
Our findings suggest that EDG1 is also recruited to the regulatory regions/promoter of genes regulated by estrogens and ERa. However, we observed stronger interaction of ERa with cyclin T1 in the presence of E 2 when compared to vehicle-treated cells. It is possible that by allowing ERa to bind more strongly to cyclin T1, E 2 allows ERa to be a more effective competitor with EDG1 for cyclin T1 interaction. This was supported by results of our GST-pull down assays, in particular when ERa was competing with the EDG1 (D150-177) NLS Figure 6 EDG1 and cyclin T1 are recruited to chromatin containing EREs and EDG1 inhibits the interaction of ERa with DNA and cyclin T1. (a) MCF7 cells were treated with either vehicle or estrogen (10 À7 M E 2 ) for either 45 or 90 min and subjected to chromatin immunoprecipitation (ChIP) assays as described in 'Materials and methods'. The ERE-containing region of the pS2 gene promoter was immunoprecipitated with ERa antibody and reimmunoprecipated with EDG1 or cyclin T1 antibody (lanes 2-4). As a negative control, DNA containing a region downstream of the ERE-containing region is shown to be not immunoprecipitated by ERa in lane 1. (b) Immunoprecipitation of ERE-containing region of the pS2 gene promoter by cyclin T1 antibody was inhibited by increased EDG1 expression. MCF7 cells were transfected with control pCMV-TAG2B vector lacking EDG1 cDNA (lanes 1 and 2) or pCMV-TAG2B-EDG1 (lanes 3 and 4). Cells were treated with either vehicle or estrogen (10 À7 M E 2 ) for 90 min and subjected to ChIP assays as described in 'Materials and methods'. The EREcontaining region of the pS2 gene promoter was immunoprecipitated with ERa antibody and reimmunoprecipated with EDG1 or cyclin T1 antibody. In (a, b), 'input control' represents PCR for 2% of total chromatin used in each reaction. Total MCF7 cell lysates used for ChIP experiments were run on a 12.5% polyacrylamide gel and subjected to Western blot analysis to detect FLAG-EDG1 as described in 'Materials and methods'. NSB is a nonspecific band. Autoradiographs are representative of two to three separate experiments each EDG1 repression of estrogen receptor alpha activity BM Wittmann et al mutant that show weak interaction with ERa. We observed repression of ERa transcription by the EDG1 (D150-177) NLS deletion mutant, whose interaction with ERa is decreased but is still able to interact with cyclin T1. These findings suggest that the interaction of EDG1 with cyclin T1 alone is more of a determinant than the recruitment of EDG1 to chromatin by ERa in the ability of EDG1 to repress ERa-mediated transcription.
As stated previously, P-TEFb kinase activity is responsible for the phosphorylation of Serine 2 of RNAP II CTD and is involved in transcriptional elongation (Marshall et al., 1996; Kim and Sharp, 2001; Orphanides and Reinberg, 2002) . Estrogen-stimulated ERa transcription complexes cycle on and off the promoter, resulting in initiation and reinitiation of transcription (Shang et al., 2000; Metivier et al., 2003) . It has been shown that the cycling off of ERa transcription complexes appeared to be dependent upon the phosphorylation state of RNAP II (Shang et al., 2000) . Transiently overexpressing EDG1 not only results in repression of transcription, but EDG1 also appears to inhibit ERa binding to DNA. Thus, it is possible that transiently overexpressed EDG1 may be inhibiting the ability of ERa to initiate and/or reinitiate transcription through inhibition of the phosphorylation of RNAP II CTD.
Our findings are not only significant in terms of ERa transcriptional regulation but also in terms of breast cancer. The recent findings by Michels et al. (2003) and Yik et al. (2003) , demonstrating that EDG1/HEXIM1 is part of an inhibitory complex with 7SK for P-TEFb, are relevant to the involvement of P-TEFb in breast cancer. We had previously shown that EDG1 expression was inhibited by estrogen, EDG1 could inhibit breast cell growth, and expression of EDG1 was significantly decreased in breast tumors, suggesting a possible role in estrogen initiation of breast cancer (Wittmann et al., 2003) . Several studies from other laboratories suggest that P-TEFb is a potential therapeutic target. Anchorage-independent colony formation of HeLa cells and H1299 (lung cancer) cells is inhibited though oligomerization chain reaction (OCR)-mediated inactivation of CDK9 (Napolitano et al., 2003) . Flavopiridol, a drug currently in clinical trials as a possible cancer therapy agent, is a very potent inhibitor of P-TEFb activity (Chao and Price, 2001 ). The inhibition of P-TEFb may play a role in the observed synergistic action of flavopiridol and the erbB2 antagonist, Herceptin, in breast cancer cells (Nahta et al., 2003) . The synergism appears to be at least partially due to downregulation of epidermal growth-factor receptor (EGFR) expression (possibly by flavopiridol). Furthermore, flavopiridol has been shown to inhibit cyclin D1 promoter activity and decrease cyclin D1 mRNA levels, a gene directly regulated by estrogens (Castro-Rivera et al., 2001) , in breast cancer cells (Carlson et al., 1999) . Consistent with these findings are our results that implicate cyclin T1 in E 2 -induced cyclin D1 expression.
The results presented within, along with previous studies, suggest that EDG1 is a highly regulated inhibitor of transcriptional elongation. Based on this, loss of expression of EDG1, as we previously observed in multiple breast tumors, may result in altered expression of genes. Of particular interest would be genes known to be regulated by estrogens, which may result in breast tumorigenesis and/or aberrant proliferation. Such studies would provide a better understanding of the role of EDG1 in estrogen-initiated breast tumorigenesis. Studies are in progress to determine what genes undergo altered expression when EDG1 expression is lost. Since EDG1 may regulate transcriptional elongation, global regulation of gene expression might be expected. However, several findings argue against this. While we observe inhibition by EDG1 of transcriptional activity of other nuclear receptors, we did not see inhibition of the VP16 transcriptional activator (data not shown). Conversely, DNA microarray analyses of hearts from cyclin T1 transgenic mice indicate selective increases in subsets of genes, rather than a global increase in mRNA expression, when compared to nontransgenic mice (Sano et al., 2004) . That transcriptional inhibition by EDG1 extends beyond the ERa does not diminish our findings; our studies suggest for the first time that ERa-mediated gene expression involves a complex interplay between the ERa, EDG1 and the transcriptional elongation machinery, with EDG1 modulating a novel functional interaction between ERa and cyclin T1.
Materials and methods
Plasmids
The EDG1 clone, pAD-GAL4-2.1-EDG1, and the human homologue of EDG1, HEXIM1, were obtained as previously described (Wittmann et al., 2003) . The EDG1 cDNA clone was released by NcoI/XbaI digestion, blunted and inserted into SalI/SmaI-digested and blunted pCMV5 vector to make pCMV5-EDG1. pGEX2T-EDG1, which encodes full-length EDG1 in frame with GST was constructed by inserting NcoI/ XbaI-digested and blunted EDG1 fragment into BamHIdigested and blunted pGEX2 T vector (Amersham Biosciences, Piscataway, NJ, USA).
To make FLAG epitope-tagged EDG1 and truncated EDG1 constructs, full-length EDG1 and deletions of the EDG1 ORF were generated, respectively, by PCR using the full-length EDG1 plasmid, pCMV5-EDG1, as template. Reactions with forward and reverse PCR primers were performed by using Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA, USA). Each forward primer contained an ATG and identical Kozac sequence and each reverse primer contained a stop codon. PCR fragments for full-length and truncated EDG1 were purified, digested with EcoRV and XhoI, and cloned into the EcoRV/XhoI site of pCMV-TAG2B in frame with the FLAG epitope (Stratagene). Construction of NLS-deleted EDG1 (D150-177) mutant was previously described (Ouchida et al., 2003 To make pCMV5-EDG1 deletion mutants, pCMV-TAG2B-EDG1 C-terminus and N-terminus mutants were digested with EcoRI and XhoI. Inserts were gel purified and cloned into the EcoRI/SalI site of pCMV5. To make pGEX4T-EDG1 and -EDG1 deletion mutants, pCMV5-EDG1 and -EDG1 deletion mutants were digested with EcoRI and XhoI. EDG1 inserts were gel purified and cloned into EcoRI/XhoI sites of pGEX4 T. To make GAL4DBD-EDG1 and , pCMV-TAG2B-EDG1 and pCMV-TAG2B-EDG1 , respectively, were XhoI-digested, blunted, and then BamHI-digested. EDG1 inserts were gel purified and inserted into HindIII-digested, blunted, and BamHI-digested pM2, in frame with the GAL4 DNA-binding site.
To make pCMV-TAG2B-ERa A/B and -ERa E/F , the Nterminus (A/B) and C-terminus (E/F) regions of ERa were generated by PCR using pBSK-ERa as template. BamHI/ EcoRI-digested ERaA/B PCR products were inserted into BamHI/EcoRI-digested pCMV-TAG2B vector in frame with the FLAG epitope. BamHI-digested ERa E/F PCR products were inserted into BamHI-digested pCMV-TAG2B vector in frame with the FLAG epitope.
ERa A/B PCR primers: To make pcDNA-cyclin T1 mutants, pGEX-cyclin T1 mutants (Wei et al., 1998; Fujinaga et al., 1999) were digested with BamHI/EcoRI. Cyclin T1 inserts were gel purified and inserted into BamHI/EcoRI-digested pcDNA. pSUPER-cyclin T1 siRNA was constructed by annealing to its complement an oligonucleotide that specifies a 19-nucleotides sequence derived from the cyclin T1 gene and separated by a short spacer from the reverse complement of the same 19-nucleotide sequence: gatccccgcaaggacttagcacagacttcaagagagtctgtgctaagtccttgctttt tggaaa. Oligonucleotides were ligated to the pSUPER vector (Brummelkamp et al., 2002) .
In vitro translation and protein-protein interaction assays
In vitro transcription and translation of ERa full-length, ERa A/B domain, ERa E/F domain, cyclin T1 full-length, T1 , T1 , and T1 were performed using the Promega TNT kit (Promega, Madison, WI, USA) according to the manufacturer's recommendation. GST-pull down assays were previously described (Montano et al., 1999) . Quantitative analyses were performed on a Macintosh computer using the public domain NIH Image program (developed at the National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/).
Tissue culture and transfections
Breast epithelial cells (MCF10A, MDA-MB-231, and T47D) were obtained from ATCC and maintained according to their recommended protocols. CHO, 293T, and MCF7 cells were maintained and transfected as previously described (Montano et al., 1999) . Chloramphenicol acetyltransferase (CAT) assays and b-galactosidase assay were performed as previously described (Montano et al., 1999) . Statistical analysis was performed using Student's t-Test.
Immunoprecipitation and immunoblotting
To examine the interaction between ERa and EDG1, MCF7 cells were grown in phenol red-free media containing charcoalstripped serum with no ligand, 17b-estradiol (E 2 , 10 À8 M), or TOT (10 À7 M) for 24 h. Cells were lysed in lysis buffer (50 mM Tris pH 7.5, 7.5 mM EDTA, 10% glycerol, 0.6 M NaCl), in the presence of protease inhibitors (1.0 mM Phenylmethylsulfonylfluoride, 0.1 mg/ml Leupeptin, 50 mg/ml Pepstatin A, 50 mg/ml Aprotinin), and 20 mM Sodium Molybdate (stabilizes receptor proteins). Whole-cell extracts (WCE) were cleared by centrifugation for 30 min at 46 000 r.p.m. For use in co-immunoprecipitation experiments, 500 mg of WCE proteins were incubated with 8.25 mg protein A for further clearing. For EDG1 immunoprecipitation, 8.25 mg of EDG1 (peptide 154-171) polyclonal rabbit IgG antibody (linked to 8.25 mg protein A) was incubated with extracts overnight at 41C. An equal concentration of normal rabbit IgG linked to protein A was used as a control. The beads were washed two times with stringent RIPA buffer (100 mM Tris pH 8.3, 2 mM EDTA pH 8.0, 0.1% SDS, 0.5% deoxycholate, 0.5% NP-40), and washed three times with 0.01 M PBS, pH 7.4 (0.14 M NaCl, 1.47 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 ). Samples were boiled and eluted in IP buffer (50 mM Tris pH 6.8, 10% BME, 2% SDS, 30% glycerol, 0.025% Bromophenol Blue). Immunoprecipitated proteins were separated on a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane.
To examine the interaction between cyclin T1 and ERa, plasmids encoding HA epitope-tagged cyclin T1 and/or ERa (total amount of plasmids were set at 10 mg using empty vector) were transfected in 293T (10 7 ) cells with calcium phosphate. At 12 h after transfection, the cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% deoxycholate, 0.02% SDS, 1 mM EDTA, pH 7.5) containing protease inhibitors and precleared with 30 ml of Protein A-Sepharose (Amersham Biosciences, Piscataway, NJ, USA). Cell lysates were then incubated with 0.2 mg of anti-HA or anti-ERa (both antibodies are from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or IgG followed by 20 ml of Protein G-Sepharose. After washing extensively with RIPA buffer containing 0.5 M NaCl, the bound proteins were separated in 10% SDS-PAGE gel followed by Western blotting. To detect endogenous interaction between cyclin T1 and ERa, MCF7 cells were processed and precleared as described above. Cell lysates were then incubated with 0.2 mg of anti-cyclin T1 or anti-ERa (both antibodies are from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or IgG followed by 20 ml of Protein G-Sepharose. After washing extensively with RIPA buffer containing 0.5 M NaCl, the bound proteins were separated in 10% SDS-PAGE gel followed by Western blotting.
ERa was detected according to the manufacturer's recommendations, using the 1D5 monoclonal mouse anti-ERa IgG antibody (Lab Vision, Fremont, California) and an HRPconjugated goat anti-mouse IgG secondary antibody (Pierce, Rockford, IL, USA). EDG1 was detected using the EDG1 (peptide 154-171) polyclonal rabbit antibody at a 1 : 1000 dilution (2.2 mg/ml) and an HRP-conjugated anti-rabbit IgG secondary antibody (Amersham Biosciences, Piscataway, NJ, USA). HA-cyclin T1 was detected using anti-HA (Santa Cruz Biotechnology) and an HRP-conjugated goat anti-mouse IgG secondary antibody. For immunoblotting, cyclin D1 was detected using anti-cyclin D1 (Lab Vision, Fremont, CA, USA) and HRP-conjugated anti-rabbit IgG secondary antibody. ERa, EDG1, cyclin T1, and cyclin D1 signals were detected using ECL Western Blotting Analysis System (Amersham Biosciences, Piscataway, NJ, USA). To control for unequal protein loading, some blots were stripped of antibody using Re-Blot Plus Mild Antibody Stripping Solution (Chemicon International, Temecula, CA, USA) according to the manufacturer's protocol and reblotted with GAPDH monoclonal antibody (1 : 2000; Chemicon International, Temecula, CA, USA).
Detection of FLAG-EDG1 and mutant FLAG-EDG1 expression
CHO cells were grown on either plastic culture dishes (for Western analyses) or coverslips (for immunofluorescence).
Cells were transfected with varying amounts of pCMV-TAG2B-EDG1 or pCMV-TAG2B-EDG1 deletion mutants for either 10 or 24 h as shown in Figure 2 . Cells used for Western analysis were lysed as previously described (Wittmann et al., 2003) . FLAG-EDG1 and FLAG-EDG1 deletion mutants were detected using the FLAG M2 mouse monoclonal antibody (1 : 7500 dilution) (Sigma Chemical Co., St. Louis, MO, USA) and an HRP-conjugated goat antimouse IgG secondary antibody (1 : 75 000 dilution) (Pierce, Rockford, IL, USA). FLAG signal was detected using Super Signal West Femto according to the manufacture's recommendations (Pierce). Immunostaining was previously described (Wittmann et al., 2003) . Cells were immunostained with FLAG antibody according to the manufacturer's recommendations and goat, anti-mouse Alexa 594 secondary antibody (1 : 500 dilution; Molecular Probes, Eugene, OR, USA). Cells were also subjected to a DAPI nuclear counterstain.
ChIP assays
MCF7 cells were plated on five 150 mm plates/treatment. Some cells were transiently transfected at 70% confluency with either 12.5 mg pCMV-TAG2B-alone or 12.5 mg pCMV-TAG2B-EDG1. Cells were grown for 24 h and then treated with vehicle or 17b-estradiol (E 2 , 10 À7 M) for 45 or 90 min. ChIP assays were performed using a modified form of the Upstate Biotech (Lake Placid, NY, USA) protocol as described previously (Bianco et al., 2005) except that preclear, diluted lysate was incubated with 5 mg of polyclonal anti-ERa IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Crosslinked complexes were eluted from the immunoprecipitate by incubation with an elution buffer (1% SDS, 50 mM NaHCO 3 ) at room temperature for 30 min. The reaction is then diluted 1 : 20 in Re-IP buffer (1% Triton X-100, 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl pH 8.0, 140 mM NaCl and 1 mM PMSF) followed by reimmunoprecipitation with either EDG1 or cyclin T1 antibody. Samples were then processed as described previously (Bianco et al., 2005) . DNA containing ERE from the pS2 gene promoter was detected by PCR (2 ml input) using the following primers, A (5 0 ggccatctctcactatgaatcacttctgc) and B (5 0 ggcaggctctgtttgcttaaagagcg). DNA containing a region downstream of the EREcontaining region in the pS2 gene promoter was detected using the primers, C (5 0 caatggccaccatggagaacaaggt) and D (5 0 gaggacgttggcatgaacagtcaaa). Quantitative analyses were performed using the NIH Image program.
Abbreviations CLP-1, cardiac lineage protein 1; ERa, estrogen receptor a; E 2 , 17b-estradiol; TOT, trans-hydroxytamoxifen; EDG1, estrogen down regulated gene 1; HEXIM1, hexamethylene-bis-acetamide-inducible protein 1; P-TEFb, positive transcription elongation factor b; RNAP II, RNA polymerase II; CTD, carboxy terminal domain; ERE, estrogen receptor response element; ChIP, chromatin immunoprecipitation; NLS, nuclear localization signal.
